跳至主要内容
临床试验/KCT0005895
KCT0005895
招募中
未知

A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of KBL693 on atopic dermatitis in children

Kobiolabs0 个研究点目标入组 159 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Diseases of the skin and subcutaneous tissue
发起方
Kobiolabs
入组人数
159
状态
招募中
最后更新
5年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
5年前
研究类型
Interventional Study
性别
All

研究者

发起方
Kobiolabs

入排标准

入选标准

  • 1\) A person who agrees to participate in this clinical trial and has voluntarily signed a Informed consent form with his/her
  • parents (or legal representative).
  • 2\) A person who are over 2 years of age and under 16 years of age.
  • 3\) A person who have intermittent or persistent atopic dermatitis symptoms for more than six months
  • 4\) A person whose SCORAD score is 25 to 50 points (mild\-modelate) in Visit 1 and 2\.
  • 5\) A person diagnosed with atopic dermatitis according to the diagnosis criteria of Hanifin and Rajka.

排除标准

  • 1\) A person who has severe skin diseases and systemic diseases other than atopic dermatitis.
  • 2\) A person who has administered systemic antibiotics, systemic corticosteroids, and antihistamines in relation to atopic
  • dermatitis within four weeks of the start of the clinical trial.
  • 3\) A person who administers systemic immunosuppressants within 12 weeks of the clinical trial.
  • 4\) A person who administers medicine, herbal medicine, and health functional foods to improve atopic dermatitis within one
  • week of the start of the clinical trial.
  • 5\) A person who has taken probiotics health functional foods, consistently fermented milk, and digestive (at least four times
  • a week) within one week of the start of the clinical trial.
  • 6\) A person who has received phototherapy within four weeks of the start of the clinical trial.
  • 7\) A person who has plans to participate in other clinical trials during clinical trial(excluding observational research).

结局指标

主要结局

未指定

相似试验